Cue Biopharma (CUE) Interest & Investment Income (2018 - 2026)

Cue Biopharma has disclosed Interest & Investment Income across 9 years of filings, most recently posting $157000.0 for Q2 2026.

• In Q2 2026, Interest & Investment Income fell 20.71% year-over-year to $157000.0; the TTM figure through Jun 2026 stood at $735000.0 (down 26.57% YoY), while the FY2025 annual figure was $807000.0, down 50.25% from the prior year.
• Interest & Investment Income came in at $157000.0 for Q2 2026 at Cue Biopharma, down from $158000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $905000.0 in Q4 2023 to a low of $8000.0 in Q1 2022.
• Average Interest & Investment Income over 5 years is $368529.4, with a median of $290000.0 recorded in 2024.
• Year-over-year, Interest & Investment Income soared 16113.44% in 2022 and plunged 69.75% in 2025.
• Over 5 years, Interest & Investment Income stood at $632000.0 in 2022, then surged by 43.2% to $905000.0 in 2023, then tumbled by 67.96% to $290000.0 in 2024, then slumped by 45.52% to $158000.0 in 2025, then declined by 0.63% to $157000.0 in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $157000.0 in Q2 2026, $158000.0 in Q4 2025, and $222000.0 in Q3 2025.